BASEL MEDICAL GROUP LTD (BMGL) Fundamental Analysis & Valuation
NASDAQ:BMGL • VGG0864B1031
Current stock price
0.62 USD
0 (0%)
At close:
0.65 USD
+0.03 (+4.84%)
After Hours:
This BMGL fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. BMGL Profitability Analysis
1.1 Basic Checks
- BMGL had negative earnings in the past year.
- BMGL had a negative operating cash flow in the past year.
1.2 Ratios
- Looking at the Return On Assets, with a value of -58.63%, BMGL is doing worse than 89.00% of the companies in the same industry.
- Looking at the Return On Equity, with a value of -201.53%, BMGL is doing worse than 79.00% of the companies in the same industry.
- The Return On Invested Capital of BMGL (7.76%) is better than 76.00% of its industry peers.
- Measured over the past 3 years, the Average Return On Invested Capital for BMGL is significantly above the industry average of 8.50%.
- The last Return On Invested Capital (7.76%) for BMGL is well below the 3 year average (21.92%), which needs to be investigated, but indicates that BMGL had better years and this may not be a problem.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -58.63% | ||
| ROE | -201.53% | ||
| ROIC | 7.76% |
ROA(3y)-10.88%
ROA(5y)N/A
ROE(3y)-45.27%
ROE(5y)N/A
ROIC(3y)21.92%
ROIC(5y)N/A
1.3 Margins
- Looking at the Operating Margin, with a value of 4.72%, BMGL is in line with its industry, outperforming 60.00% of the companies in the same industry.
- In the last couple of years the Operating Margin of BMGL has declined.
- The Profit Margin and Gross Margin are not available for BMGL so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 4.72% | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3Y-59.77%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. BMGL Health Analysis
2.1 Basic Checks
- BMGL has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
- Compared to 1 year ago, BMGL has more shares outstanding
- BMGL has a worse debt/assets ratio than last year.
2.2 Solvency
- BMGL has an Altman-Z score of -0.24. This is a bad value and indicates that BMGL is not financially healthy and even has some risk of bankruptcy.
- With a Altman-Z score value of -0.24, BMGL is not doing good in the industry: 78.00% of the companies in the same industry are doing better.
- A Debt/Equity ratio of 0.56 indicates that BMGL is somewhat dependend on debt financing.
- BMGL has a Debt to Equity ratio (0.56) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.56 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -0.24 |
ROIC/WACC0.9
WACC8.58%
2.3 Liquidity
- A Current Ratio of 1.31 indicates that BMGL should not have too much problems paying its short term obligations.
- The Current ratio of BMGL (1.31) is comparable to the rest of the industry.
- BMGL has a Quick Ratio of 1.26. This is a normal value and indicates that BMGL is financially healthy and should not expect problems in meeting its short term obligations.
- BMGL has a Quick ratio (1.26) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.31 | ||
| Quick Ratio | 1.26 |
3. BMGL Growth Analysis
3.1 Past
- BMGL shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -416.72%.
- The Revenue has grown by 8.02% in the past year. This is quite good.
- The Revenue has been growing slightly by 2.03% on average over the past years.
EPS 1Y (TTM)-416.72%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-604.19%
Revenue 1Y (TTM)8.02%
Revenue growth 3Y2.03%
Revenue growth 5YN/A
Sales Q2Q%12.63%
3.2 Future
- No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
- No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. BMGL Valuation Analysis
4.1 Price/Earnings Ratio
- The Price/Earnings Ratio is negative for BMGL. In the last year negative earnings were reported.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
- BMGL's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. BMGL is cheaper than 99.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 1.67 |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A
5. BMGL Dividend Analysis
5.1 Amount
- BMGL does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
BMGL Fundamentals: All Metrics, Ratios and Statistics
0.62
0 (0%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners0.8%
Inst Owner Change-0.17%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap11.65M
Revenue(TTM)16.35M
Net Income(TTM)-10.95M
AnalystsN/A
Price TargetN/A
Short Float %1.31%
Short Ratio3.35
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 0.91 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 2.73 | ||
| P/tB | 2.73 | ||
| EV/EBITDA | 1.67 |
EPS(TTM)-0.46
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.19
FCFYN/A
OCF(TTM)-0.17
OCFYN/A
SpS0.68
BVpS0.23
TBVpS0.23
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -58.63% | ||
| ROE | -201.53% | ||
| ROCE | 9.06% | ||
| ROIC | 7.76% | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | 4.72% | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-10.88%
ROA(5y)N/A
ROE(3y)-45.27%
ROE(5y)N/A
ROIC(3y)21.92%
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)33.36%
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y-59.77%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0.88
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.56 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 1.55 | ||
| Cap/Depr | 47.15% | ||
| Cap/Sales | 3.41% | ||
| Interest Coverage | 3.79 | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.31 | ||
| Quick Ratio | 1.26 | ||
| Altman-Z | -0.24 |
F-Score1
WACC8.58%
ROIC/WACC0.9
Cap/Depr(3y)16.59%
Cap/Depr(5y)N/A
Cap/Sales(3y)1.69%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-416.72%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-604.19%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)8.02%
Revenue growth 3Y2.03%
Revenue growth 5YN/A
Sales Q2Q%12.63%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-89.8%
EBIT growth 3Y-58.95%
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-283.94%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-261.16%
OCF growth 3YN/A
OCF growth 5YN/A
BASEL MEDICAL GROUP LTD / BMGL Fundamental Analysis FAQ
What is the fundamental rating for BMGL stock?
ChartMill assigns a fundamental rating of 2 / 10 to BMGL.
What is the valuation status for BMGL stock?
ChartMill assigns a valuation rating of 1 / 10 to BASEL MEDICAL GROUP LTD (BMGL). This can be considered as Overvalued.
Can you provide the profitability details for BASEL MEDICAL GROUP LTD?
BASEL MEDICAL GROUP LTD (BMGL) has a profitability rating of 2 / 10.